Oncura

Carboplatin + Etoposide + Durvalumab: what to expect, day by day

Lung - SCLC21-day cycle8 effects documented

A chemo-plus-immunotherapy combination for small cell lung cancer. The chemo lowers blood counts significantly (with infection risk), causes hair loss and nausea; durvalumab can occasionally cause immune-related inflammation, most often of the thyroid.

Chemo (carboplatin + etoposide) plus immunotherapy (durvalumab) for extensive-stage small cell lung cancer. The chemo backbone is heavily myelosuppressive (nadir-based, days since infusion); durvalumab's immune effects can occur any time (weeks-months).

Get help straight away — this is true on any regimen, on any day.

A temperature of 100.4°F (38°C) or higher during treatment can mean a serious infection while your blood counts are low. Call your team or go to the ER — do not wait it out.

Also urgent: trouble breathing or chest pain · swelling of the face, lips or throat · new confusion or fainting · shaking chills · not being able to keep fluids down.

This is standing guidance shown to everyone. Nothing on this page is based on anything about you, and nobody is monitoring you.

Timed to the cycle

Day 1 is the day of your infusion. These are the effects a retrievable document ties to a day range for this regimen — not a prediction about you.

Neutropenia

Typically around days 7–28

A drop in infection-fighting white cells — often significant with this chemo; the low point is usually around day 10-14. A white-cell booster is frequently used.

Call your team urgently: A temperature of 100.4°F (38.0°C) or higher — an emergency.

reported by about 45-60% of people; severe in 41% · Timing from a drug-monograph reference · from Carboplatin, Etoposide

Febrile neutropenia

Typically around days 7–28

Fever occurring while white cells are low — a medical emergency needing immediate antibiotics.

Call your team urgently: Fever with feeling unwell — go to the ER and say you're on chemotherapy.

severe in 4.5% · Timing from a drug-monograph reference · from Carboplatin, Etoposide

Anemia

Typically around days 7–28

A drop in red cells causing tiredness and breathlessness, building over cycles; transfusion support is sometimes needed.

Call your team: New or worsening breathlessness, chest pain, or a racing heart.

severe in 13% · Timing from a drug-monograph reference · from Carboplatin, Etoposide

Thrombocytopenia

Typically around days 7–28

A drop in platelets (which help blood clot); the low point is usually around day 14-21. Watch for easy bruising or bleeding.

Call your team: Bleeding that won't stop, or black/tarry stools.

severe in 12% · Timing from a drug-monograph reference · from Carboplatin, Etoposide

Not tied to a cycle day

These build with the number of doses, or are measured from when treatment started, so a cycle day would be the wrong shape for them. Each keeps the timing its own source states.

Hair loss

begins ~2-4 weeks in

Hair loss is common, starting 2-4 weeks in; it grows back after treatment ends.

reported by about 31% of people; severe in 1.1% · from Etoposide, Carboplatin

Nausea

Sickness in the first 24 hours is the "acute" phase and usually peaks 2-3 hours in; anything from 24 to 120 hours is the "delayed" phase.

Usually mild-moderate and well controlled with anti-nausea medicine; can be delayed a few days.

Call your team: Can't keep fluids down for more than 12 hours.

reported by about 34% of people; severe in 0.4% · Timing from a clinical guideline · from Carboplatin, Etoposide

Fatigue

Tiredness that builds over cycles. If marked, your team may check thyroid function (an immune effect of durvalumab).

reported by about 32% of people; severe in 3.4% · from Carboplatin, Etoposide, Durvalumab

Immune-related effects (thyroid, lungs, liver)

any time on/after treatment, weeks-months

From the immunotherapy: the immune system can inflame the thyroid (most common), or less often the lungs, liver, or bowel — at any time. Report new cough/breathlessness, marked tiredness, yellowing, or diarrhea; these respond well to early treatment.

Call your team urgently: Severe breathlessness, diarrhea, or feeling very unwell — contact your team urgently.

reported by about 20% of people; severe in 5% · from Durvalumab

Where this comes from

  1. S1. Paz-Ares L, CASPIAN trial (durvalumab + platinum-etoposide, ES-SCLC) (2019) — PMID 31590988
  2. S2. Durvalumab (Imfinzi) FDA prescribing information (CASPIAN combination tables, n=265) — FDA label
  3. S3. Etoposide FDA prescribing information — FDA label

Timing windows on this page rest on:

A window appears here only where a retrievable document ties it to a drug in this regimen. Where nothing could be found, the window was removed rather than estimated — so a missing time is an honest gap, not an oversight.

Track your own cycle in Oncura →

Free, no account, nothing leaves your device.